Report
KRAS alleles: The LCS6 3′UTR variant and KRAS coding sequence mutations in the NCI-60 panel
Downloads and Tools
Volume 11, Issue 2 January 15, 2012
Pages 361 - 366
http://dx.doi.org/10.4161/cc.11.2.18794
Authors: Samrat T. Kundu, Sunitha Nallur, Trupti Paranjape, Marta Boeke, Joanne Barnes Weidhaas and Frank J. Slack
View affiliations Hide affiliations
- Samrat T. Kundu
-
Department of Molecular, Cellular and Developmental Biology; Yale University; New Haven, CT USA
- Sunitha Nallur
-
Department of Therapeutic Radiology; Yale University School of Medicine; New Haven, CT USA
- Trupti Paranjape
-
Department of Therapeutic Radiology; Yale University School of Medicine; New Haven, CT USA
- Marta Boeke
-
Department of Therapeutic Radiology; Yale University School of Medicine; New Haven, CT USA
- Joanne Barnes Weidhaas
-
Corresponding author: joanne.weidhaas@yale.edu
Department of Therapeutic Radiology; Yale University School of Medicine; New Haven, CT USA
- Frank J. Slack
-
Corresponding author: frank.slack@yale.edu
Department of Molecular, Cellular and Developmental Biology; Yale University; New Haven, CT USA
Abstract:
The KRAS-variant is a germline single nucleotide polymorphism (SNP) within the 3′ UTR of the KRAS gene predicted to disrupt a complementary binding site (LCS6) for the let-7 microRNA (miRNA). The KRAS-variant is associated with increased risk of various cancers, including lung cancer, ovarian cancer and triple-negative breast cancer, and is associated with altered tumor biology in head and neck cancer, colon cancer and melanoma. To better understand the molecular pathways that may be regulated or affected by the presence of the KRAS-variant allele in cancer cells, we examined its prevalence in the NCI-60 panel of cell lines and sought to identify common features of the cell lines that carry the variant allele. This study provides a step forward towards understanding the molecular and pathological significance of the KRAS-variant.
Received: November 14, 2011; Accepted: November 16, 2011
Preview: